Stay updated with breaking news from Pooled Results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.
First presentation of RSV Older Adult vaccine candidate's pivotal phase III efficacy and safety data New data showing Shingrix... | October 12, 2022
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV)
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr...